OSUR - OraSure Technologies, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
12.62
+0.60 (+4.99%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close12.02
Open12.18
Bid12.59 x 800
Ask12.66 x 2200
Day's Range12.16 - 12.94
52 Week Range5.23 - 18.27
Volume1,653,168
Avg. Volume1,658,745
Market Cap899.377M
Beta (5Y Monthly)0.47
PE Ratio (TTM)63.10
EPS (TTM)0.20
Earnings DateAug 04, 2020 - Aug 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.67
  • GlobeNewswire

    Diversigen, Inc. and Alimentiv Inc. Announce Collaboration Agreement for Ulcerative Colitis Research Study

    Diversigen, Inc., a subsidiary of OraSure Technologies Inc. (OSUR), and Alimentiv Inc. (formerly Robarts Clinical Trials) today announced they have signed a collaboration agreement for a research study on patients with Acute Severe Ulcerative Colitis (ASUC). The study, titled: “Pharmacokinetics of Infliximab and Tumor Necrosis Factor Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis (PROTOS Study),” is designed to provide new insights into the molecular determinants of response to infliximab (IFX) in patients with ASUC. ASUC is the most aggressive presentation of ulcerative colitis (UC), and occurs in 15 percent of adults and children with UC.

  • Hedge Funds Warming Up To OraSure Technologies, Inc. (OSUR)
    Insider Monkey

    Hedge Funds Warming Up To OraSure Technologies, Inc. (OSUR)

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]

  • GlobeNewswire

    OraSure’s DNA Genotek Subsidiary Unveils First In-Home Self-Collection Device for Metabolomics

    OraSure Technologies, Inc. (OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services is introducing the first and only commercially available device for in-home, self-collection of fecal samples for metabolomics. A product of OraSure’s DNA Genotek subsidiary, the OMNImet™·GUT (ME-200) augments the Company’s portfolio of multiomic sample collection products. “Advances in the prediction, detection, understanding, and monitoring of human diseases have increased the use of metabolomics technologies,” said Kathleen Weber, Executive Vice President, Business Unit Leader, Molecular Solutions at DNA Genotek.

  • Metabolon, Inc. and DNA Genotek Collaborate on First Ambient-Temperature Microbiome Sampling Solution for Metabolomics
    PR Newswire

    Metabolon, Inc. and DNA Genotek Collaborate on First Ambient-Temperature Microbiome Sampling Solution for Metabolomics

    Metabolon, Inc., the global leader in metabolomics, and DNA Genotek, a subsidiary of OraSure Technologies, Inc. (NASDAQ: OSUR), have collaborated to bring OMNImet™·GUT, the first device for in-home collection and ambient-temperature storage and shipping of fecal samples for metabolomics, to the research market.

  • Thomson Reuters StreetEvents

    Edited Transcript of OSUR.OQ earnings conference call or presentation 6-May-20 9:00pm GMT

    Q1 2020 OraSure Technologies Inc Earnings Call

  • GlobeNewswire

    OraSure Technologies Receives BARDA Funding for Coronavirus Antibody ELISA Using Oral Fluid Samples

    OraSure Technologies, Inc. (OSUR), a leader in point-of-care diagnostic tests, specimen collection devices and microbiome laboratory and analytical services, today announced it has been awarded a $629,217 contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to develop an Enzyme-Linked Immunosorbent Assay (ELISA) for the detection of human anti-SARS-CoV-2 antibodies in oral fluid specimens. Currently, there are no oral fluid-based COVID antibody tests available with automated assays. This support from BARDA will help OraSure complete development and file for FDA Emergency Use Authorization (EUA), which would allow the laboratory-based microplate antibody test for oral fluid samples to enter into the U.S. market.

  • GlobeNewswire

    OraSure’s Oragene®•Dx included in EUA allowing at-home saliva collection for use with Phosphorus SARS-CoV-2 test

    OTTAWA, June 08, 2020 -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and.

  • GlobeNewswire

    OraSure Technologies, Inc. Announces Exercise of Option to Purchase Additional Shares of Common Stock

    In total, 9,200,000 shares of common stock of the Company are being sold in the offering. With the exercise by the underwriters of their option to purchase such additional shares, after the underwriting discount and estimated offering expenses, OraSure expects to receive net proceeds of approximately $94.9 million. J.P. Morgan Securities LLC, Citigroup and Evercore Group L.L.C. are acting as joint book‑running managers of the offering and as representatives of the underwriters.

  • GlobeNewswire

    OraSure Technologies, Inc. Prices Underwritten Offering of Common Stock

    After the underwriting discount and estimated offering expenses, OraSure expects to receive net proceeds of approximately $82.48 million. In addition, OraSure has granted the underwriters a 30-day option to purchase up to an additional 1,200,000 of shares of its common stock. J.P. Morgan Securities LLC, Citigroup and Evercore Group L.L.C. are acting as joint book-running managers of the offering and as representatives of the underwriters.

  • GlobeNewswire

    OraSure Technologies, Inc. Announces Proposed Public Offering of Common Stock

    J.P. Morgan Securities LLC, Citigroup Global Markets Inc. and Evercore Group L.L.C. are acting as joint book running managers of the offering and as representatives of the underwriters. UBS Investment Bank and Raymond James & Associates, Inc. are acting as co-managers. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of common stock offered in the public offering.

  • GlobeNewswire

    OraSure Technologies, Inc. Announces Purchase of UrSure, Inc.

    OraSure Technologies, Inc. (OSUR), a leader in point of care diagnostic tests and specimen collection and stabilization devices, and microbiome laboratory and analytical services, today announced that it has entered into a definitive agreement to acquire privately owned UrSure, Inc. (“UrSure”) for cash. Based in Boston, UrSure is developing and commercializing products that measure adherence to HIV medications including pre-exposure prophylaxis or PrEP, the daily medication to prevent HIV. PrEP has been shown to be 99 percent effective at preventing HIV infection when taken daily, adding another tool to help ensure that patients stay healthy.

  • GlobeNewswire

    OraSure Technologies Appoints Lelio Marmora to Board of Directors

    OraSure Technologies, Inc. (OSUR), a leader in point of care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced the appointment of Lelio Marmora as a member of the Company’s Board of Directors effective June 1, 2020. Mr. Marmora, the former executive director of Unitaid, will serve as a Class III Director with an initial term expiring at the Company’s 2021 Annual Meeting of Stockholders.

  • GlobeNewswire

    OraSure Technologies to Present at the Jefferies 2020 Healthcare Conference

    BETHLEHEM, Pa., May 26, 2020 -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, and microbiome laboratory.

  • GlobeNewswire

    OraSure’s OMNIgene®·ORAL Kit Included in EUA Granted to P23 Labs for At-Home Collection of Saliva Samples for SARS-CoV-2 Test

    OTTAWA, May 22, 2020 -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and.

  • GlobeNewswire

    Diversigen Inc. Selected by Nom Nom™ as the Preferred Provider for Metagenomics and Microbiome Sequencing and Analysis Services

    Diversigen, Inc., a subsidiary of OraSure Technologies Inc. (OSUR), and Nom Nom™, a direct-to-consumer pet health brand, today announced that Nom Nom has selected Diversigen as their preferred provider for metagenomics and microbiome sequencing and analysis services. Diversigen will also serve as Nom Nom’s central lab for the generation of high quality microbiome data.

  • GlobeNewswire

    OraSure Technologies to Present at the UBS Virtual Global Healthcare Conference

    BETHLEHEM, Pa., May 15, 2020 -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Dr..

  • GlobeNewswire

    OraSure Technologies to Hold Virtual Annual Meeting of Stockholders on May 19, 2020

    BETHLEHEM, Pa., May 14, 2020 -- OraSure Technologies, Inc. (NASDAQ: OSUR), announced that its 2020 Annual Meeting of Stockholders will be a completely virtual meeting,.

  • GlobeNewswire

    OraSure Technologies, Inc. Consolidates Microbiome Services Subsidiaries

    OraSure Technologies, Inc. (OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that its Diversigen and CoreBiome subsidiaries have combined their microbiome service offerings under the Diversigen name. The rebrand highlights the combined companies’ unparalleled scientific bench strength, state-of-the-art laboratory, ability to translate data to insights and collective focus on quality and service. The unified Diversigen operation will continue to offer the science-driven, customized solutions for metagenomics sequencing, bioinformatics, and statistical analysis for the study of the microbiome for which CoreBiome and Diversigen are known.

  • OraSure Technologies (OSUR) Q1 2020 Earnings Call Transcript
    Motley Fool

    OraSure Technologies (OSUR) Q1 2020 Earnings Call Transcript

    With us today are Dr. Stephen Tang, president and chief executive officer; and Mr. Roberto Cuca, chief financial officer. Dr. Tang and Mr. Cuca will begin with opening statements, which will be followed with a question-and-answer session. Tang, you should note that this call may contain certain forward-looking statements, including statements with respect to revenues, expenses, profitability, earnings or loss per share and other financial performance, product development, performance, shipments and markets, business plans, regulatory filings and approvals, expectations and strategies.

  • GlobeNewswire

    OraSure Announces 2020 First Quarter Financial Results and Provides COVID-19 Update

    BETHLEHEM, Pa., May 06, 2020 -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices and microbiome laboratory and.

  • GlobeNewswire

    OraSure Technologies Appoints Lisa Nibauer as Infectious Disease Business Unit Lead

    OraSure Technologies, Inc. (OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that Lisa Nibauer has been appointed Executive Vice President, Business Unit Leader, Infectious Disease. Mr. Zezzo has agreed to work with Ms. Nibauer to ensure smooth and successful transition of duties, while maintaining his current pivotal role in OraSure’s COVID-19 activities.

  • GlobeNewswire

    DNA Genotek’s ORAcollect®·RNA kit included in EUA granted to Biocerna SARS-CoV-2 test

    OTTAWA, May 04, 2020 -- DNA Genotek Inc., a leading provider of sample collection kits and end-to-end services and a wholly-owned subsidiary of OraSure Technologies, Inc..

  • Can You Imagine How Jubilant OraSure Technologies' (NASDAQ:OSUR) Shareholders Feel About Its 173% Share Price Gain?
    Simply Wall St.

    Can You Imagine How Jubilant OraSure Technologies' (NASDAQ:OSUR) Shareholders Feel About Its 173% Share Price Gain?

    When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, you can make far...

  • GlobeNewswire

    OraSure Technologies Earnings Conference Call Invitation

    2020 First Quarter Earnings Conference Call Wednesday, May 6, 2020, 5:00 p.m. ET BETHLEHEM, Pa., April 09, 2020 -- OraSure Technologies, Inc. (NASDAQ: OSUR) has.

  • Lehigh Valley medical device company working on at-home COVID-19 test
    American City Business Journals

    Lehigh Valley medical device company working on at-home COVID-19 test

    The Bethlehem company received federal funding for the project from Biomedical Advanced Research and Development Authority.